The new world of RNA diagnostics and therapeutics.
Cell cycle regulation
Epigenetics
RNA evolution
RNA structure
Splicing
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
29 Jul 2023
29 Jul 2023
Historique:
received:
16
06
2023
accepted:
06
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) on 27-28 March at the IRCCS Regina Elena National Cancer Institute. This meeting entitled "The New World of RNA diagnostics and therapeutics" highlightes the significant progress in the RNA field made over the last years. Research moved from pure discovery towards the development of diagnostic biomarkers or RNA-base targeted therapies seeking validation in several clinical trials. Non-coding RNAs in particular have been the focus of this workshop due to their unique properties that make them attractive tools for the diagnosis and therapy of cancer.This report collected the presentations of many scientists from different institutions that discussed recent oncology research providing an excellent overview and representative examples for each possible application of RNA as biomarker, for therapy or to increase the number of patients that can benefit from precision oncology treatment.In particular, the meeting specifically emphasized two key features of RNA applications: RNA diagnostic (Blandino, Palcau, Sestito, Díaz Méndez, Cappelletto, Pulito, Monteonofrio, Calin, Sozzi, Cheong) and RNA therapeutics (Dinami, Marcia, Anastasiadou, Ryan, Fattore, Regazzo, Loria, Aharonov).
Identifiants
pubmed: 37507791
doi: 10.1186/s13046-023-02752-8
pii: 10.1186/s13046-023-02752-8
pmc: PMC10386627
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Informations de copyright
© 2023. The Author(s).
Références
Commun Biol. 2020 Nov 13;3(1):677
pubmed: 33188287
Nat Methods. 2022 Oct;19(10):1208-1220
pubmed: 35618955
RNA. 2010 Jul;16(7):1436-45
pubmed: 20547774
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):140-148
pubmed: 34666950
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5005-13
pubmed: 27503895
J Exp Clin Cancer Res. 2023 Mar 17;42(1):66
pubmed: 36932446
Blood Adv. 2019 Nov 26;3(22):3613-3625
pubmed: 31743393
Oncotarget. 2018 Nov 23;9(92):36411-36412
pubmed: 30559926
Clin Cancer Res. 2020 Aug 1;26(15):3936-3946
pubmed: 32357963
Theranostics. 2022 Oct 24;12(17):7420-7430
pubmed: 36438490
Mol Cancer. 2022 Jul 22;21(1):152
pubmed: 35869553
Front Cell Dev Biol. 2021 Nov 26;9:781365
pubmed: 34901025
Annu Rev Genet. 2018 Nov 23;52:223-247
pubmed: 30208292
Mol Cancer. 2020 Mar 30;19(1):69
pubmed: 32228602
Int J Mol Sci. 2021 Aug 25;22(17):
pubmed: 34502076
Blood Adv. 2020 Nov 24;4(22):5616-5630
pubmed: 33186461
Med. 2023 Jan 13;4(1):15-30.e8
pubmed: 36513065
Blood Rev. 2021 May;47:100776
pubmed: 33229139
Clin Cancer Res. 2021 Nov 1;27(21):5961-5978
pubmed: 34407972
J Exp Med. 2005 Jul 4;202(1):85-96
pubmed: 15983063
Leukemia. 2019 Jan;33(1):132-147
pubmed: 29946193
Gut. 2021 May;70(5):829-837
pubmed: 33028667
Biol Direct. 2011 May 18;6:23
pubmed: 21592325
Biochem Biophys Rep. 2021 Feb 02;26:100937
pubmed: 33553693
Clin Cancer Res. 2020 Jun 15;26(12):2956-2971
pubmed: 31969334
Comput Struct Biotechnol J. 2022 Jul 28;20:4003-4008
pubmed: 35983233
Ann Oncol. 2022 Apr;33(4):395-405
pubmed: 35091076
Sci Rep. 2021 Feb 24;11(1):4435
pubmed: 33627690
Mol Cancer. 2022 Jan 28;21(1):33
pubmed: 35090471
Cell. 2013 Oct 10;155(2):345-356
pubmed: 24120135
Front Immunol. 2020 Jul 24;11:1590
pubmed: 32793228
Front Immunol. 2021 Oct 12;12:740890
pubmed: 34712230
EMBO J. 2019 Jun 3;38(11):
pubmed: 31000523
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747